SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

Search

Laboratorios Farmaceuticos Rovi SA

Fermé

SecteurSoins de santé

79.55 1.66

Résumé

Variation du prix de l'action

24h

Actuel

Min

79.55

Max

79.8

Chiffres clés

By Trading Economics

Revenu

-33M

43M

Ventes

7.9M

218M

P/E

Moyenne du Secteur

33.602

67.147

BPA

0.834

Marge bénéficiaire

19.539

Employés

1,950

EBITDA

-21M

63M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+9.26% upside

Dividendes

By Dow Jones

Prochains Résultats

6 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

79M

4.1B

Ouverture précédente

77.89

Clôture précédente

79.55

Sentiment de l'Actualité

By Acuity

50%

50%

155 / 347 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 mai 2026, 23:47 UTC

Résultats

National Australia Bank Warns of Economic Shock as 1st Half Profit Falls -- Update

3 mai 2026, 22:35 UTC

Résultats

National Australia Bank Holds Dividend Despite 19% 1st Half Profit Drop

3 mai 2026, 23:39 UTC

Market Talk

Gold Edge Higher Amid Signs of Resilience -- Market Talk

3 mai 2026, 23:34 UTC

Market Talk

Oil Declines Amid Mild Risk-on Sentiment -- Market Talk

3 mai 2026, 23:32 UTC

Résultats

National Australia Bank Warns of Economic Shock as 1H Profit Falls -- Update

3 mai 2026, 23:30 UTC

Market Talk

Nickel Industries Result Shows Power of Higher Prices -- Market Talk

3 mai 2026, 23:20 UTC

Market Talk

RBA Likely to Hike Rates; Guidance and Board Split Key -- Market Talk

3 mai 2026, 23:16 UTC

Acquisitions, Fusions, Rachats

GameStop Is Offering to Buy eBay for $56 Billion, CEO Ryan Cohen Says -- WSJ

3 mai 2026, 22:57 UTC

Acquisitions, Fusions, Rachats

GameStop Is Offering to Buy eBay For $56 Billion, CEO Ryan Cohen Says -- WSJ

3 mai 2026, 22:57 UTC

Acquisitions, Fusions, Rachats

GameStop Has Roughly 5% Stake in eBay, Cohen Says -- WSJ

3 mai 2026, 22:57 UTC

Acquisitions, Fusions, Rachats

GameStop Offering to Buy eBay for $125 a Share, or About $56 Billion, CEO Ryan Cohen Says -- WSJ

3 mai 2026, 22:57 UTC

Acquisitions, Fusions, Rachats

GameStop Is Prepared to Run Proxy Fight If eBay Isn't Receptive to a Deal, Cohen Says -- WSJ

3 mai 2026, 22:57 UTC

Acquisitions, Fusions, Rachats

GameStop Has Around $20 Billion in Debt Financing Committed From TD Bank, Cohen Says -- WSJ

3 mai 2026, 22:45 UTC

Market Talk

Global Equities Roundup: Market Talk

3 mai 2026, 22:45 UTC

Market Talk

Low-Cost Miners in Spotlight Amid High Energy Prices -- Market Talk

3 mai 2026, 22:20 UTC

Résultats

National Australia Bank Holds Dividend Despite 19% 1H Profit Drop

3 mai 2026, 22:08 UTC

Résultats

NAB's 1H Included Previously Announced A$1.35B Software Amortization Charge>NAB.AU

3 mai 2026, 22:05 UTC

Résultats

NAB 1H Net Interest Income A$9.16B Vs. A$8.445B>NAB.AU

3 mai 2026, 22:05 UTC

Résultats

NAB 1H Credit Impairment Charge A$706M Vs. A$348M>NAB.AU

3 mai 2026, 22:05 UTC

Résultats

NAB 1H Operating Expenses A$5.02B Vs. A$4.81B>NAB.AU

3 mai 2026, 22:04 UTC

Résultats

NAB 1H Net Interest Margin 1.81%>NAB.AU>NAB.AU

3 mai 2026, 22:03 UTC

Résultats

NAB 1H Cash Return on Equity Ex-Large Notable Items 11.6%>NAB.AU

3 mai 2026, 22:03 UTC

Résultats

NAB 1H Cash Return on Equity 8.5%>NAB.AU

3 mai 2026, 22:02 UTC

Résultats

NAB 1H CET1 Capital Ratio 11.65% Vs. 12.01%>NAB.AU

3 mai 2026, 22:02 UTC

Résultats

NAB 1H Cash Earnings A$2.64B>NAB.AU

3 mai 2026, 22:02 UTC

Résultats

NAB 1H Cash Earnings Ex-Notable Items A$3.59B Vs. A$3.58B>NAB.AU

3 mai 2026, 22:01 UTC

Résultats

National Australia Bank Keeps Dividend at A$0.85 >NAB.AU

3 mai 2026, 22:01 UTC

Résultats

National Australia Bank 1H Rev A$11.16B Vs. A$10.28B >NAB.AU

3 mai 2026, 22:01 UTC

Résultats

National Australia Bank 1H Net A$2.75B Vs. Net A$3.41B >NAB.AU

3 mai 2026, 15:06 UTC

Résultats

Berkshire's Greg Abel Marks His First Annual Meeting as CEO. We'd Give Him a B-Plus. -- Barrons.com

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

9.26% hausse

Prévisions sur 12 Mois

Moyen 86.75 EUR  9.26%

Haut 90 EUR

Bas 83.5 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

155 / 347Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat